New hATTR Treatments Under Review for their ‘Value for Money’
Two vitally important reviews are underway for patisiran and inotersen, new treatments that have been trialed for hATTR patients. One review is led by the National Institute for Health and Clinical Excellence (NICE) in the UK. (more…)
ARC CEO Named Representative of Patient Engagement Collaborative
To strengthen patient involvement, the U.S. Food and Drug Administration (FDA) and the Clinical Trials Transformation Initiative (CTTI) announced the launch of the Patient Engagement Collaborative (PEC). (more…)
ARC Provides Vital Feedback for Evaluation of New hATTR Treatments
The Institute of Clinical and Economic Review (ICER), is an independent organization that seeks to improve healthcare value by providing comprehensive clinical and cost-effectiveness analyses of treatments. (more…)
ARC Launches Version Two of Powerful Amyloidosis Diagnostic App
A recent ARC survey showed that patients typically see four or more physicians before getting accurately diagnosed, and often those who were misdiagnosed were receiving treatment for their misdiagnosis. The Clinical Resources App was developed to provide healthcare professionals with...
Join our email list to stay up to date on the latest Amyloidosis news.
In this ARC TALKS webinar, Dr. Heather Landau discussed current treatment options for relapsed and refractory AL amyloidosis patients. Dr. Landau also talked about the current testing methodology used to monitor a patient’s disease status, and the role maintenance therapy may play in the management of relapsed AL amyloidosis.
In addition to describing considerations that may factor into recommended treatment plans for patients, Dr. Landau shared details on novel therapies being evaluated in clinical trials.
Original Presentation Date:
June 29, 2023
Key Webinar Highlights:
0:00 — Introduction
3:15 — Relapsed / Refractory AL Amyloidosis Overview
20:31 — Managing Relapsed / Refractory AL Amyloidosis
38:27 — Q&A
39:03 — How do patients know if they’re heading towards relapsed / refractory AL amyloidosis?
41:47 — How often do you monitor for relapsed AL amyloidosis?
42:57 — What is “minimal residual disease?”
46:54 — How common is relapsed AL amyloidosis?
48:52 — Is Venetoclax a therapy option?
50:28 — Alternatives after Daratumumab?
52:38 — How important is increased screening?
55:01 — How are light-chain and M spike levels correlated?